Ann: Development of world first BARD1 Breast Cancer Test, page-276

Do notknow what ulterior motives of some posters here but has helped us otherinvestors to get some really insightful answers from  DB, BrokeNurse,Kwed and few others. THANK YOU to all!

 

Hot offthe press: Credit Suisse Equities has bought a 5% stake – looks like theirSmall & Mid Cap fund has bought 42m shares ! This is great news and theyare active investors – not passive. ! https://www.credit-suisse.com/lu/en/asset-management/solutions-capabilities/equities/small-and-mid-cap.html

Fact ofthe matter is Biotechs have attracted a lot attention globally. I encourage allbelievers to read the below article in Business Insider on IPO success in 2018so far. 

https://www.*.com/top-biotech-ipos-of-2018-2018-9?international=true&r=US&IR=T

In thefirst nine months of 2018, 47 Biotech IPOs raised USD 4.6bn in capital. Theseare in various stages of development - on average raising apprx USD100/IPO. Sothe momentum and sentiment is to Biotecs in 2018. 

Beloware the top 5 IPOs and you need to read to understand more. Summary below.

Rubius Therapeutics usesreprogrammed red blood cells to treat conditions like cancer. IPOraised $241m

Tricida is developing therapeutics to treatrenal, metabolic and cardivascular disease. IPO raised $222m

MorphoSys is developingantibodies for cancer, Alzheimer's Disease, infectious diseases, cardiovasculardiseases, and inflammation. IPO raised $207m

Kiniska Pharmaceuticals develops drugstargeting autoinflammatory and autoimmune disease. Phase 1 trial IPO$152m

Autolus Therapeutics develops CAR-T cellimmunotherapies for blood and solid tumor cancers. It expects to reportproof-of-concept data from five programs in 2019. IPO $150m

BD1breakthrough technology is helpful to the mankind - whether you are an investoror not. This is the starting point. BD1 is is undervalued compared to some ofthe US valuations – and this is the correct comparion for a biotech, cannotjust compare to OZ peers.

For me, BD1ticks all the boxes

1.     Biotech is the sector to be in –great momentum globally

2.     Now Credit Suisse Equities hasnow taken 5% stake – just announced. They have a Small cap and Mid Cap strategy.This seems a direct investment by Credit Suisse Small cap fund. This is greatnews

3.     BD1 is playing in a billiondollar segment

4.     Credible management

5.     Breakthrough technology

6.     Enough cash through to 1H 2019 –but should be an issue to raise capital now!. I will definitely put more moneyin!

7.     Progress on patenting and  good NPD pipeline

Bd1 Vs USIPOs and current values of Biotecs, BD1 is worth at least AUD100m if not more.These opportunities do not come very often so grab it. Enough said.

Tomorrowwill be fun -

GLTAHfrom Europe